by Clinical Neuropsychologist Online | Tuesday, October 1, 2024 | Dementia
Abstract INTRODUCTION Limbic-predominant age-related TAR DNA-binding protein of 43 kDa encephalopathy neuropathologic change (LATE-NC) staging criteria were updated in 2023. We evaluated this updated staging using National Alzheimer’s Coordinating Center data....
by Clinical Neuropsychologist Online | Tuesday, October 1, 2024 | Dementia
Abstract Introduction The angiotensin-converting enzyme 2 (ACE2), which is expressed in cerebral vascular endothelial cells (CVECs), has been currently identified as a functional receptor for SARS-CoV-2. Methods We specifically induced injury to ACE2-expressing CVECs...
by Clinical Neuropsychologist Online | Tuesday, October 1, 2024 | Dementia
Abstract INTRODUCTION Biomarkers for Alzheimer’s disease neuropathologic change (ADNC) have been instrumental in developing effective disease-modifying therapeutics. However, to prevent/treat dementia effectively, we require biomarkers for non-AD...
by Clinical Neuropsychologist Online | Tuesday, October 1, 2024 | Dementia
Abstract INTRODUCTION Blood-based biomarkers offer a promising approach for the detection of neuropathologies from repetitive head impacts (RHI). We evaluated plasma biomarkers of amyloid, tau, neurodegeneration, and inflammation in former football players. METHODS...
by Clinical Neuropsychologist Online | Tuesday, October 1, 2024 | Dementia
Abstract INTRODUCTION Understanding the impact of biomarker-based dementia risk estimation in people with mild cognitive impairment (MCI) and their care partners is critical for patient care. METHODS MCI patients and study partners were counseled on Alzheimer’s...
